Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years

Urinary Tract Infections Clinical Trial

Official title:

A Phase 1, Open-Label Study in Healthy Participants Aged 18 to 65 Years to Investigate the CYP3A4 Induction Potential of GSK3882347

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05760261
• Other study ID #: 213252
• Status: Suspended
• Phase: Phase 1
• Start date: March 6, 2023
• Est. completion date: August 1, 2023

Study information

• Verified date: July 2023
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to determine the magnitude and clinical relevance of a potential drug-drug interaction of GSK3882347 with midazolam (MDZ) in healthy participants. This study assesses the effect of GSK3882347 as an inducer of Cytochrome P450 3A4 (CYP3A4) using MDZ, a sensitive substrate of hepatic and intestinal CYP3A4. The study will investigate MDZ pharmacokinetic (PK) effect in two dosing periods: Period 1: A single dose of MDZ Period 2: 14-days of once daily repeat dosing of GSK3882347 followed by single dose of MDZ co-administered with GSK3882347 on Day 15 (14-days has been selected as this duration is required in order to maximize any potential CYP3A4 enzyme induction).

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 30
• Est. completion date: August 1, 2023
• Est. primary completion date: August 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A participant with a clinical abnormality or laboratory parameter(s) not specifically listed in the exclusion or exclusion criteria that is outside the reference range for the population being studied may be included only if the investigator, in consultation with the Medical Monitor (if required), agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
• Body weight at least 50.0 kilogram (kg) (110 pound [lbs.]) for males and 45.0 kg (99 lbs.) for females; and body mass index (BMI) within the range 18.5 - 32.0 kg per meter square (kg/m^2) (inclusive).
• Male participants are eligible to participate if they agree to the following during the study intervention Period and for at least 3 days, after the last dose of study

intervention:

• Refrain from donating fresh unwashed semen

Plus, either:

• Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR
• Must agree to use contraception/barrier.
• A female participant is eligible to participate if she is not pregnant or

breastfeeding, and one of the following conditions applies:

• Is a woman of non-childbearing potential (WONCBP) . OR
• Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of lesser than (<) 1 percent (%).
• A WOCBP must have a negative highly sensitive pregnancy test [urine or serum] as required by local regulations) within 24h before the first dose of study intervention.
• The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion Criteria:

• History or presence of significant cardiovascular, respiratory, hepatic, renal, urological, gastrointestinal, metabolic, endocrinological, hematological, immunologic, dermatologic, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data or in the opinion of the investigator places the participants at unacceptable risk or would make adhering to study procedures for the duration of the study difficult. Participants who have had a gastric bypass or a cholecystectomy are excluded from the study.
• Abnormal blood pressure, as determined by the investigator.
• Alanine transferase (ALT) value greater than (>)1.5 × upper limit of normal (ULN).
• Bilirubin value >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
• The participant has a current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• The participant has congenital long QT syndrome or known prolongation of the corrected QT (QTc) interval.
• The participant has any history of heart failure.
• The participant has a family history of QT prolongation or sudden death.
• The participant has any current or previous a history of episodes of symptomatic bradycardia or bradyarrhythmia.
• The participant has a QTc >450 millisecond (msec). Note: The QTc is the QT interval corrected for heart rate according to Fridericia formula, machine, or manual overread.

11. The participant has anuria, oliguria, or impairment of renal function (GFR by Modification of diet in renal disease [MDRD] <90 milliliter per minute per 1.73 meter square [mL/min/1.73m^2] or serum creatinine > ULN or urine albumin-creatinine ratio [ACR] of =300 milligram per gram [mg/g] at screening).

• The participant must agree to and adhere to the concomitant therapy (including nondrug therapies) restrictions from the Screening Visit through to the end of the end of the study (including telephone visit).
• Participation in the study would result in loss of blood or blood products in excess of 500 milliliter (mL) within 56 days.
• Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
• Current enrolment or past participation within the last 30 days or 5 half-lives, whichever is longer, before signing of consent in any other clinical study involving an investigational study intervention or any other type of medical research.
• Current enrolment or past participation in this clinical study.
• Positive human immunodeficiency virus (HIV) antibody test.
• Presence of Hepatitis B surface antigen (HbsAg) at screening or within 3 months prior to first dose of study intervention.
• Hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
• A positive confirmation of Coronavirus disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-19.
• The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete the study.
• Regular alcohol consumption within 6 months prior to the study. An average weekly intake of >14 units for males or females. One unit is equivalent to approximately to 8 g of alcohol: a half-pint (approximately [~]240 mL) of beer, one glass (125 mL) of wine or one (25 mL) measure of spirits.
• Positive smoke breathalyzer indicative of smoking history at screening and each in-house admission to the clinical research unit or regular use of tobacco or nicotine-containing products (i.e., nicotine patches or vaporizing devices) within 3 months prior to screening.
• Regular use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to "vape".
• Any history of substance abuse or a positive urine test for drugs of abuse/ alcohol breath screen at screening or admission.
• Known hypersensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
• Contraindication for MDZ (i.e., Hypersensitivity to the active substance, benzodiazepines or to any of the excipients, myasthenia gravis, respiratory insufficiency, sleep apnea syndrome, severe hepatic impairment).
• Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.).

Related Conditions & MeSH terms

• Urinary Tract Infections

Intervention

Drug:
• Midazolam
Midazolam will be administered.
• GSK3882347
GSK3882347 will be administered.

Locations

Country	Name	City	State
United Kingdom	GSK Clinical Unit Cambridge	Cambridge

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Period 1: Area under the curve from time zero to 24 hours (AUC [0-24]) for plasma concentration of MDZ		Up to 24 hours
Primary	Period 1: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ		Up to 24 hours
Primary	Period 2: AUC (0-24) for plasma concentration of MDZ		Up to 24 hours
Primary	Period 2: AUC (0-24) for plasma concentration of 1-hydroxy-MDZ		Up to 24 hours
Primary	Period 1: AUC from time zero to last time of quantifiable concentration (AUC [0-tau]) for plasma concentration of MDZ		Up to Day 2
Primary	Period 1: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ		Up to Day 2
Primary	Period 2: AUC (0-tau) for plasma concentration of MDZ		Up to Day 15
Primary	Period 2: AUC (0-tau) for plasma concentration of 1-hydroxy-MDZ		Up to Day 15
Primary	Period 1: AUC from time zero extrapolated to infinite time (AUC [0-inf]) for plasma concentration of MDZ		Up to Day 2
Primary	Period 1: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ		Up to Day 2
Primary	Period 2: AUC (0-inf) for plasma concentration of MDZ		Up to Day 15
Primary	Period 2: AUC (0-inf) for plasma concentration of 1-hydroxy-MDZ		Up to Day 15
Primary	Period 1: Maximum plasma concentration (Cmax) of MDZ		Up to Day 2
Primary	Period 1: Cmax of 1-hydroxy-MDZ		Up to Day 2
Primary	Period 2: Cmax of MDZ		Up to Day 15
Primary	Period 2: Cmax of 1-hydroxy-MDZ		Up to Day 15
Primary	Period 1: Time to Cmax (Tmax) of MDZ		Up to Day 2
Primary	Period 1: Tmax of 1-hydroxy-MDZ		Up to Day 2
Primary	Period 2: Tmax of MDZ		Up to Day 15
Primary	Period 2: Tmax of 1-hydroxy-MDZ		Up to Day 15
Primary	Period 1: Time lag before observation of measurable concentrations (Tlag) of MDZ		Up to Day 2
Primary	Period 1: Tlag of 1-hydroxy-MDZ		Up to Day 2
Primary	Period 2: Tlag of MDZ		Up to Day 15
Primary	Period 2: Tlag of 1-hydroxy-MDZ		Up to Day 15
Primary	Period 1: Time to half-life (T1/2) of MDZ		Up to Day 2
Primary	Period 1: T1/2 of 1-hydroxy-MDZ		Up to Day 2
Primary	Period 2: T1/2 of MDZ		Up to Day 15
Primary	Period 2: T1/2 of 1-hydroxy-MDZ		Up to Day 15
Secondary	Number of participants with adverse events (AEs) and serious adverse events (SAEs)		Up to Day 15
Secondary	Number of participants with clinically significant changes in hematology laboratory values		Up to Day 15
Secondary	Number of participants with clinically significant changes in chemistry laboratory values		Up to Day 15
Secondary	Number of participants with clinically significant changes in urinalysis laboratory values		Up to Day 15
Secondary	Number of participants with clinically significant changes in vital sign values		Up to Day 15
Secondary	Number of participants with clinically significant changes in 12-lead electrocardiogram (ECG) readings		Up to Day 15
Secondary	AUC (0-24) for plasma concentration of GSK3882347		Up to 24 hours
Secondary	Plasma concentrations over the dosing interval tau (Ctau) of GSK3882347		Up to Day 15
Secondary	Oral clearance (CL/F) of GSK3882347		Up to Day 15
Secondary	Volume of distribution/ Bioavailability (Vd/F) of GSK3882347		Up to Day 15
Secondary	Mean residence time (MRT) of GSK3882347		Up to Day 15
Secondary	AUC(0-inf) for single dose of GSK3882347		Up to Day 2
Secondary	Cmax for single dose of GSK3882347		Up to Day 2
Secondary	AUC(0-tau) for repeat dose of GSK3882347		Up to Day 15
Secondary	Cmax for repeat dose of GSK3882347		Up to Day 15
Secondary	Accumulation ratio (Ro) using AUC (0-tau) for repeat dose of GSK3882347		Up to Day 15
Secondary	Time invariance using AUC(0-tau) (repeat dose) of GSK3882347		Up to Day 15
Secondary	Time invariance using AUC(0-inf) (single dose) of GSK3882347		Up to Day 2
Secondary	Achievement of steady state of GSK3882347		Up to Day 15